Amdt. dated March 17, 2008

Reply to Office Action of September 17, 2007

II. IN THE CLAIMS

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6. (Cancelled)

Claim 7. (Original) An siRNA oligoribonucleotide having a nucleotide sequence shown in any one of SEQ ID Nos. 20 to 34.

Claim 8. (Currently amended) An siRNA having a nucleotide sequence oligoribonucleotide which hybridizes under stringent conditions either with an RNA region of HCV having a sequence complementary to a nucleotide sequence shown in any one of SEO ID Nos. 20 to 34 the oligoribonucleotide according to Claim 7 or an RNA region of HCV hybridizing under stringent conditions with said <u>nucleotide</u> sequence oligoribonucleotide.

Claim 9. (Currently amended) An siRNA oligoribonucleotide having represented by a nucleotide sequence consisting of 19 to 23 contiguous bases in any one of the nucleotide sequences shown in SEQ ID Nos. 47 to 55.

Claim 10. (Currently amended) An siRNA having a nucleotide sequence oligoribonucleotide which hybridizes under stringent conditions either with an RNA region of HCV having a sequence complementary to a nucleotide sequence consisting of 19 to 23 contiguous bases in any one of the nucleotide sequences shown in SEQ ID Nos. 47 to 55 the oligoribonucleotide according to Claim 9 or an RNA region of HCV hybridizing under stringent conditions with said nucleotide sequence oligoribonucleotide.

Claim 11. (Currently amended) A vector which expresses the siRNA oligoribonucleotide according to Claim 7 1.

Appln. No. 10/543,078

Amdt. dated March 17, 2008

Reply to Office Action of September 17, 2007

Claim 12. (Currently amended) A therapeutic agent for hepatitis C containing as an active ingredient the <u>siRNA</u> oligoribonucleotide or peptide nucleic acid according to Claim 7 1.

Claim 13. (Cancelled)

Claim 14. (Currently amended) A vector which expresses the <u>siRNA</u> oligoribonucleotide according to Claim 9.

Claim 15. (Currently amended) A therapeutic agent for hepatitis C containing as an active ingredient the <u>siRNA</u> oligoribonucleotide or peptide nucleic acid according to Claim 9.

Claim 16. (Previously Presented) A therapeutic agent for hepatitis C containing as an active ingredient the vector according to Claim 11.

Claim 17. (Cancelled)

Claim 18. (New) An siRNA having a nucleotide sequence shown in any one of SEQ ID Nos. 20 to 34 or a nucleotide sequence consisting of 19 to 23 contiguous bases in any one of nucleotide sequences shown in SEQ ID Nos. 47 to 55, wherein 7 or less nucleotides are deleted, substituted or added, and being able to inhibit HCV replication by hybridizing with the RNA of HCV.